Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P L Collins

Showing results (111-120 of 160) with videos related to

Pageof 16
Sort By:
Journal of Virology|October 3, 2001
A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeysM H Skiadopoulos, S R Surman, J M Riggs, et al.
Vaccine|March 1, 1991
Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV)B R Murphy, G A Prince, P L Collins, et al.
Vaccine|November 1, 1993
A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSVJ E Crowe, P L Collins, W T London, et al.
Journal of Virology|November 1, 1987
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunityM K Spriggs, B R Murphy, G A Prince, et al.
Journal of Virology|January 11, 2000
Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccineU J Buchholz, H Granzow, K Schuldt, et al.
Virology|July 1, 1993
Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNAP L Collins, M A Mink, M G Hill, et al.
Vaccine|June 8, 2001
Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backboneT Tao, M H Skiadopoulos, F Davoodi, et al.
Journal of Virology|January 1, 1989
Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virusR A Olmsted, B R Murphy, L A Lawrence, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 5, 1995
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine developmentP L Collins, M G Hill, E Camargo, et al.
Vaccine|April 9, 1999
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challengeT Tao, M H Skiadopoulos, A P Durbin, et al.
Pageof 16

Showing results (111-120 of 160) with videos related to

Sort By:
Pageof 16
Journal of Virology|October 3, 2001
A chimeric human-bovine parainfluenza virus type 3 expressing measles virus hemagglutinin is attenuated for replication but is still immunogenic in rhesus monkeysM H Skiadopoulos, S R Surman, J M Riggs, et al.
Vaccine|March 1, 1991
Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV)B R Murphy, G A Prince, P L Collins, et al.
Vaccine|November 1, 1993
A comparison in chimpanzees of the immunogenicity and efficacy of live attenuated respiratory syncytial virus (RSV) temperature-sensitive mutant vaccines and vaccinia virus recombinants that express the surface glycoproteins of RSVJ E Crowe, P L Collins, W T London, et al.
Journal of Virology|November 1, 1987
Expression of the F and HN glycoproteins of human parainfluenza virus type 3 by recombinant vaccinia viruses: contributions of the individual proteins to host immunityM K Spriggs, B R Murphy, G A Prince, et al.
Journal of Virology|January 11, 2000
Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccineU J Buchholz, H Granzow, K Schuldt, et al.
Virology|July 1, 1993
Rescue of a 7502-nucleotide (49.3% of full-length) synthetic analog of respiratory syncytial virus genomic RNAP L Collins, M A Mink, M G Hill, et al.
Vaccine|June 8, 2001
Construction of a live-attenuated bivalent vaccine virus against human parainfluenza virus (PIV) types 1 and 2 using a recombinant PIV3 backboneT Tao, M H Skiadopoulos, F Davoodi, et al.
Journal of Virology|January 1, 1989
Processing, surface expression, and immunogenicity of carboxy-terminally truncated mutants of G protein of human respiratory syncytial virusR A Olmsted, B R Murphy, L A Lawrence, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 5, 1995
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine developmentP L Collins, M G Hill, E Camargo, et al.
Vaccine|April 9, 1999
A live attenuated chimeric recombinant parainfluenza virus (PIV) encoding the internal proteins of PIV type 3 and the surface glycoproteins of PIV type 1 induces complete resistance to PIV1 challenge and partial resistance to PIV3 challengeT Tao, M H Skiadopoulos, A P Durbin, et al.
Pageof 16